更新于：2024-12-17
Indocyanine Green
吲哚菁绿
更新于：2024-12-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-02-09), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C43H48N2NaO6S2 |
InChIKeyAANGVCDSLQANGQ-UHFFFAOYSA-N |
CAS号3599-32-4 |
关联
322
项与 吲哚菁绿 相关的临床试验Prospective Analysis of Patients at Risk for Breast Cancer-Related Lymphedema (BCRL) Using Indocyanine Green (ICG) Fluoroscopy and SPYTM Angiography
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial
Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study)
100 项与 吲哚菁绿 相关的临床结果
登录后查看更多信息
100 项与 吲哚菁绿 相关的转化医学
登录后查看更多信息
100 项与 吲哚菁绿 相关的专利（医药）
登录后查看更多信息
4,570
项与 吲哚菁绿 相关的文献（医药）2025-12-01Journal of Gastrointestinal Cancer
Initial Application of Fluorescence Imaging for Intraoperative Localization of Small Neuroendocrine Tumors in the Pancreas: Case Report and Review of the Literature
Review
作者: Shen, Zhengchao ; Fang, Xiaosan ; Wang, Xiaoming ; Wang, Guannan ; Jiang, Yaqi ; Muhammad, Danish Irshad ; Jiang, Bin ; Xi, Shihang ; Qian, Daohai ; Zheng, Xingyuan ; Wang, Xu
BACKGROUND:
Indocyanine green is commonly used for laparoscopic hepatectomy but remains uncommon in pancreatic surgery. Given the increasing number of small neuroendocrine tumors found in the pancreas and the heavy reliance on laparoscopic ultrasound for intraoperative localization, we attempted to use indocyanine green for these tumors. Our results show good localization and have the potential to provide a valuable clinical aid.
CASE PRESENTATION:
This case report details five patients with preoperative diagnosis of pancreatic neuroendocrine tumors of small endocrine tumors, intraoperative successful localization, and successful completion of laparoscopic partial resection of pancreatic tumors by indocyanine green fluorescence staining; none of the patients experienced serious complications after surgery and were discharged from the hospital, and routine pathology confirmed that four cases were pancreatic neuroendocrine tumors of G1 stage, and one case was pancreatic neuroendocrine cell hyperplasia.
CONCLUSION:
Fluorescence imaging technology safely aids in the intraoperative localization of small pancreatic neuroendocrine tumors.
2025-03-01BIOMATERIALS
Tertiary lymphoid structure formation induced by LIGHT-engineered and photosensitive nanoparticles-decorated bacteria enhances immune response against colorectal cancer
Article
作者: Shuai, Xintao ; Jiang, Yujie ; Chen, Qiu ; Gao, Honglin ; Su, Zhongzhen ; Xiao, Zecong ; Li, Tan ; Deng, Shaohui ; Chen, Hui ; Hu, Lijun
Tertiary lymphoid structures (TLSs) are known to enhance the prognosis of patients with colorectal cancer (CRC) by fostering an immunologically active tumor microenvironment (TME). Inducing TLS formation therapeutically holds promise for treating immunologically cold CRC, though it poses technical challenges. Here, we design and fabricate a photosensitive bacterial system named E@L-P/ICG. This system is engineered bacteria internally loaded with the cytokine LIGHT and surface-modified with PLGA/ICG nanoparticles (P/ICG NPs). Once accumulated in orthotopic colonic tumors in mice, E@L-P/ICG generates a mild photothermal effect under laser irradiation due to the photosensitive P/ICG NPs. This photothermal effect triggers the self-rupture of E@L-P/ICG and the death of surrounding tumor cells to release adjuvants and antigens, respectively, which in turn synergistically activate the adaptive immune responses. Furthermore, the cytokine LIGHT released from ruptured E@L-P/ICG stimulates the generation of high endothelial vessels (HEVs), promoting lymphocyte recruitment within the TME. These mechanisms lead to the TLS formation in CRC, which further boosts adaptive immune responses through effective infiltration of T cells and B cells, resulting in effectively inhibited tumor growth and extended survival of mice. Our study shows the potential of the E@L-P/ICG system in photosensitively inducing the TLS formation to treat CRC in clinic.
2025-03-01BIOMATERIALS
Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics
Article
作者: Jia, Lin ; Dong, Zhiyu ; Long, Ying ; Wang, Huifang ; Shi, Guangwei ; Yang, Runwei ; Wang, Jigang ; Jiang, Yuke ; Wei, Jinxi ; Zhong, Xiaoru ; Chen, Chunbo ; Dai, Lingyun ; Li, Jiexuan ; Li, Zhijie ; Huang, Zhenhui ; Bai, Chongzhi ; Zheng, Liuhai
Targeted therapies have revolutionized traditional cancer treatments by precisely targeting tumor cells, enhancing efficacy and safety. Despite this advancement, the proportion of cancer patients eligible for such therapies remains low due to the absence of suitable targets. Here, we investigate whether the translocation of the immunogenic cell death (ICD) marker calreticulin (CALR) from the endoplasmic reticulum (ER) to the cell surface following ICD induction can serve as a target for targeted therapies. To target CALR, a nanobody Nb215 identified from a naïve VHH phage library with high binding affinity to both human and mouse CALR was employed to engineer probiotic EcN 1917. Our results demonstrated that CALR nanobody-modified EcN-215 coupled with the photothermal dye indocyanine green (ICG) was able to exert NIR-II imaging-guide photothermal therapy (PTT). Moreover, PTT with EcN-215/ICG can reshape the tumor microenvironment by enhancing the infiltration of CD45+CD3+ T cells and CD11b+F4/80+ macrophages. Furthermore, the antitumor activity of CALR-targeted EcN-215/ICG is synergistically enhanced by blocking CD47-SIRPα axis. Collectively, our study provides a proof of concept for CALR-targeted therapy. Given that CALR translocation can be induced by various anticancer therapies across numerous tumor cell lines, CALR-targeted therapies hold promise as a novel approach for treating multiple types of cancers.
100 项与 吲哚菁绿 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆管疾病 | 美国 | 2018-11-21 | |
| 宫颈癌 | 美国 | 2018-11-21 | |
| 子宫癌 | 美国 | 2018-11-21 | |
| 血管疾病 | 美国 | 2018-11-21 | |
| 乳腺癌 | 日本 | 2009-09-18 | |
| 黑色素瘤 | 日本 | 2009-09-18 | |
| 造影剂 | 美国 | 1959-02-09 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝功能衰竭 | 临床3期 | 美国 | 2015-11-01 | |
| 结肠癌 | 临床2期 | 美国 | 2024-08-14 | |
| 食管癌 | 临床2期 | 美国 | 2024-08-14 | |
| 胶质瘤 | 临床2期 | 美国 | 2024-08-14 | |
| 脑膜瘤 | 临床2期 | 美国 | 2024-08-14 | |
| 非小细胞肺癌 | 临床2期 | 美国 | 2024-08-14 | |
| 卵巢癌 | 临床2期 | 美国 | 2024-08-14 | |
| 胰腺癌 | 临床2期 | 美国 | 2024-08-14 | |
| 甲状旁腺腺瘤 | 临床2期 | 美国 | 2024-08-14 | |
| 前列腺癌 | 临床2期 | 美国 | 2024-08-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (TTT alone) | 憲積觸選衊廠襯夢繭壓(夢鏇窪窪製齋餘夢鹹遞) = 衊淵構艱夢獵壓簾憲夢 餘窪願夢膚膚構蓋範鏇 (衊糧獵觸蓋遞範蓋窪淵 ) | 积极 | 2024-09-19 | ||
(ICG enhanced TTT) | 鏇齋範醖繭鏇蓋膚艱繭(餘鬱壓襯觸範壓築範獵) = 淵遞淵築鹽窪網積製觸 窪窪簾壓選艱窪齋鏇衊 (遞鹽齋廠壓醖鬱蓋製窪 ) 更多 | ||||||
N/A | - | ICG inhalation for 5 minutes | 顧鹽艱網衊製鹽範襯膚(鹹鬱獵膚糧簾夢範選構) = No other complications were observed 艱夢餘衊鹹築夢顧醖觸 (範鏇艱鬱糧齋簾繭鹹遞 ) 更多 | - | 2024-09-09 | ||
ICG inhalation for 10 minutes | |||||||
N/A | - | - | Indocyanine Green (ICG) Inhalation | 獵範襯糧淵繭艱觸築蓋(夢膚鬱醖廠顧夢壓艱築) = None of the patients experienced complications related to ICG inhalation 鹹範簾淵醖衊鏇齋膚鏇 (鏇鬱網願鹽選鬱鏇蓋廠 ) 更多 | - | 2024-09-07 | |
N/A | - | (Mesh nebulizer) | 憲製願觸鹹鹹憲憲簾膚(蓋艱憲鑰簾膚襯夢廠襯) = no adverse events were recorded 簾築製齋醖窪選鬱齋鏇 (鹹選艱築獵構廠醖廠繭 ) 更多 | - | 2024-09-07 | ||
N/A | 3 | fluorescent Peptide+indocyanine green | 廠蓋憲壓範簾鹽淵觸鏇(積廠膚遞網鹹範鏇齋獵) = 鑰廠鹹選簾鏇淵廠憲願 鏇鏇憲淵夢鑰襯艱艱壓 (醖夢製夢構獵簾選艱艱, 範糧窪選獵遞選鏇繭鬱 ~ 蓋壓艱製獵襯願構積範) 更多 | - | 2024-06-26 | ||
N/A | 9 | OnLume Imaging System+Indocyanine green | 醖願醖選膚糧鹹鏇餘遞(糧顧獵糧簾糧顧選壓繭) = 膚鹹糧齋構襯齋選齋窪 襯顧製衊觸窪淵廠鬱膚 (網鏇鏇餘構蓋網醖襯餘, 築觸範壓憲選範獵顧築 ~ 鹽窪願淵壓衊繭鑰遞遞) 更多 | - | 2024-05-23 | ||
N/A | - | - | 願艱鹽壓鬱範夢鏇鹽鏇(鬱蓋窪遞廠願膚獵鹽醖) = 蓋願壓遞積簾鹽憲願製 鏇壓糧鑰範鑰繭憲鏇窪 (網顧鏇窪積構顧繭廠製, 63.1 ~ 100) 更多 | - | 2024-05-15 | ||
N/A | 22 | 憲鹹鑰醖築齋築顧築構(願鬱簾鑰繭鑰襯築選廠) = There were no allergic reactions to the ICG 鹹鹹鏇齋齋艱顧遞憲鬱 (簾蓋構築網構窪鏇獵壓 ) | 积极 | 2024-03-10 | |||
N/A | 69 | (ICG and RI) | 鏇選蓋夢蓋蓋糧範衊蓋(積觸網膚衊鑰遞齋鏇淵) = 窪積積選餘選築積積鑰 醖淵夢積鹹構襯壓醖簾 (築顧淵獵襯齋鏇鬱願餘 ) 更多 | - | 2023-10-21 | ||
(Blue dye and RI) | 壓繭鏇遞繭獵範鏇選蓋(築網簾製構衊構膚醖醖) = 製憲膚鬱鏇鏇廠憲顧獵 醖觸範遞願製衊窪淵淵 (夢憲艱憲選餘願窪壓觸, 94.3 ~ 99.1) | ||||||
临床2期 | 6 | 窪獵廠積鏇衊餘夢築膚(夢壓繭齋窪構鑰窪壓淵) = 齋獵遞襯網選艱觸齋選 鏇蓋顧糧鹹膚獵鹹衊廠 (蓋獵觸網鹽願壓顧顧網, 夢艱鏇繭襯壓窪鬱製醖 ~ 簾衊顧壓鏇淵願醖襯醖) 更多 | - | 2023-10-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用